Nonviral approaches for cancer gene therapy

Pharmaceutical Gene Delivery Systems

Volumn , Issue , 2003, Pages 279-319

  Lui, Vivian Wai Yan ^a   Huang, Leaf ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908446789     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (154)

1. Marshell E. Gene therapy death prompts review of adenovirus vector. Science 1999; 26:2244-2245.
2. Lai SL, Perng RP, Hwang J. p53 Gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 2000; 7:64-70.
3. Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, Chen L, Chen SH. Immunomodulatory gene Therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastates in a mouse model. J Natl Cancer Inst 2000; 92:931-936.
4. Myers KJ, Dean NM. Sensible use of antisense: how to use oligonucleotides as research tools. Trends Pharmacol Sci 2000; 21:19-23.
5. Koller E, Gaarde WA, Monia BP. Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol Sci 2000; 21:142-148.
6. He YK, Lui VW, Baar J, Wang L, Shurin M, Almonte C, Watkins SC, Huang L. Potentiation of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. Gene Ther 1998; 5:1462-1471.
7. Qian C, Drozdzik M, Caselmann WH, Prieto J. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000; 32:344-351.
8. Bost F, McKay R, Dean N, Mercola D. The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem 1997; 272:33422-33429.
9. Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M, Kudo T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res 2000; 60:760-765.
10. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997; 20:165-177.
11. Flanagan WM. Antisense comes of age. Cancer Metastasis Rev 1998; 17:169-176.
12. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 1997; 15:537-541.
13. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 1998; 16:59-63.
14. Lui VW, He Y, Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol Ther 2001; 3(2):169-177.
15. Hsieh SS, Malerczyk C, Aigner A, Czubayko F. ERbB-2 expression is, rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer 2000; 86:644-651.
16. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribo-zyme-mediated down-regulation of ErbB-4 in estrogen receptor- positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999; 59: 5315-5322.
17. Funato T, Ishii T, Kambe M, Scanlon KJ, Sasaki T. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther 2000; 7:495-500.
18. Halatsch ME, Schmidt U, Botefur IC, Holland JF, Ohnuma T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg 2000; 92:297-305.
19. Leirdal M, Sioud M. Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Br J Cancer 1999; 80:1558-1564.
20. Rossi JJ. Ribozymes to the rescue: repairing genetically defective mRNAs. Trends Genet 1998; 14:295-295.
21. Nielsen PE, Egholm M. An introduciton to PNA. In: Nielsen PE, Egholm M, eds. Peptide Nucleic Acids: Protocols and Applications. Wymondhan, UK: Horizon Scientific Press, 1999, p 1-19.
22. Raney KD, Hamilton SE, Corey DR. Interactions of peptide nucleic acids with DNA processing enzymes. In: Nielsen PE, Egholm M, eds. Peptide Nucleic Acids: Protocols and Applications. Wyomondham, UK: Horizon Scientific Press, 1999; pp 241-251.
23. Good L, Nielsen PE. Antisense effects in Escherichia coli. In: Nielsen PE, Egholm M, eds. Peptide Nucleic Acids: Protocols and Applications. Wymondham, UK: Horizon Scientific Press, 1999, pp 213-220.
24. Shammas MA, Simmons CG, Corey DR, Reis RJ. Telomerase inhibition by peptide nucleic acids reverses ‘immortality’ of transformed human cells. Oncogene 1999; 18:6191-6200.
25. Wang G, Seidman MM, Glazer PM. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 1996; 271:802-805.
26. Vasquez KM, Wang G, Havre PA, Glazer PM. Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res 1999; 27:1176-1181.
27. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligo-deoxyribonucleotide binds to the c- myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 1991; 88:8227-8231.
28. Barre FX, Ait-Si-Ali S, Giovannangeli C, Luis R, Robin P, Pritchard LL, Helene C, Harel-Bellan A. Unambiguous demonstration of triple-helix-directed gene modification. Proc Natl Acad Sci USA 2000; 97:3084-3088.
29. Giovannangeli C, Perrouault L, Escude C, Nguyen T, Helene C. Specific inhibition of in vitro transcription elongation by triplex- forming oligonucleotide-intercalator conjugates targeted to HIV proviral DNA. Biochemistry 1996; 35:10539-10548.
30. Klysik J, Kinsey BM, Hua P, Glass GA, Orson FM. A 15-base acridine conjugated oligodeoxynucleotide forms triplex DNA with its IL-2R alpha promoter target with greatly improved avidity. Bioconjug Chem 1997; 8:318-326.
31. Gee JE, Yen RL, Hung M-C, Hogan ME. Triplex formation at the rat neu oncogene promoter. Gene 1994; 149:109-114.
32. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999; 35:2039-2057.
33. Piche A, Rancourt C. A role for intracellular immunization in chemosensitization of tumor cells? Gene Ther 1999; 6:1202-1209.
34. Hung MC, Wang SC, Hortobagyi G. Targeting HER-2/neu-overexpressing cancer cells with transcriptional repressor genes delivered by cationic liposome. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego Academic Press, 1999, pp 357-377.
35. Yu D, Hung M-C. The erbB2 gene as a cancer therapeutic target and the tumor-and metastasis-supressing function of E1A. Cancer Metastasis Rev 1998; 17:195-202.
36. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
37. Kouraklis G. Progress in cancer gene therapy. Acta Oncol 1999; 38:675-683.
38. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16:2221-2232.
39. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for nonsmall cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998; 25:33-37.
40. Gjertsen BT, Logothetis CL, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 1999; 17:345-351.
41. Chang FL, Ling YF, Lai MD. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH- 8301 human bladder cancer cells. Anticancer Res 2000; 20:329-336.
42. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p161NK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3:313-319.
43. Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M, Saito I, Kanegae Y, Matsuda H. Cancer gene therapy using a pro-apoptosic gene, caspase-3. Gene Ther 1999; 6:1952-1959.
44. Tsao YP, Huang SJ, Chang JL, Hsieh JT, Pong RC, Chen SL. Adenovirus-mediated p21((WAF1/SDII/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 1999; 73:4983-4890.
45. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349:1137-1141.
46. Dorai T, Olsson CA, Katz AE, Buttyan R. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone refractory human prostate cancer. Prostate 1997; 32:246-258.
47. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998; 58:2134-2140.
48. Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol 1976; 16:207-248.
49. Taniguchi T, Rigg A, Lemoine NR. Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis [editorial]. Gene Ther 1998; 5: 1011-1013.
50. Oku T, Tjuvajev JG, Miyagawa T, Sasajima T, Joshi A, Joshi R, Finn R, Claffey KP, Blasberg RG. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, proliferation of human melanoma intracerebral xenografts. Cancer Res 1998; 58:4185-4192.
51. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000; 6:2094-2103.
52. Sacco MG, Caniatti M, Cato EM, Frattini A, Chiesa G, Ceruti R, Adorni F, Zecca L, Scanziani E, Vezzoni P. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 2000; 60:2660-2665.
53. Cao Y, O’Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases [published erratum appears J Clin Invest 1998 Dec 1; 102(11):2031]. J Clin Invest 1998; 101:1055-1063.
54. Kanitakis J, Euvrard S, Bourchany D, Faure M, Claudy A. Expression of the nm23 metastasis-suppressor gene product in skin tumors. J Cutan Pathol 1997; 24:151-156.
55. Kim JW, Cho HS, Kim JH, Hur SY, Kim TE, Lee JM, Kim IK, Namkoong SE. AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis. Lab Invest 2000; 80:587-594.
56. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90:11307-11311.
57. Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 2000; 18:515-520.
58. Hwu P, Yannelli J, Kriegler M, Anderson WF, Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, Mule J, et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol 1993; 150:4104-4115.
59. Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000; 105:1383-1393.
60. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH. Cytokine gene therapy gliomas: induction of reactive CD4+ T cells by interleukin-4- transferred 9L gliosarcoma is essential for protective immunity. Cancer Res 2000; 60:2449-2457.
61. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60:397-403.
62. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50:7820-7825.
63. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma geneinserted tumor cells. J Immunol 1993; 150:1458-1470.
64. Kim YS, Sonn CH, Bothwell ALM. Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity. Gene Therapy 2000; 7:837-843.
65. Hirschowitz EA, Naama HA, Evoy D, Lieberman MD, Daly J, Crystal RG. Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchyma. Cancer Gene Ther 1999; 6:491-498.
66. Cao X, Wang Q, Ju DW, Tao Q, Wang J. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene. J Exp Clin Cancer Res 1999; 18:191-200.
67. Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S, Ichihashi M. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 2000; 18:206-213.
68. Khew-Goodall Y, Gamble JR, Vadas MA. Regulation of adhesion and adhesion molecules in endothelium by transforming growth factor-beta. Currt Top Microbiol Immunol 1993; 184:187-199.
69. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4:193-201.
70. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT, Antitransforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumori-genicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF- beta interactions in human breast cancer progression. J Clin Invest 1993; 92:2569-2576.
71. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996; 93:2909-2914.
72. Yang NS, Hogge GS, MacEwen EG. Particle-mediated gene delivery applications to canine and other larger animial systems. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, 1999, pp 171-190.
73. White SA, LoBuglio AF, Arani RB, Pike MJ, Moore SE, Barlow DL, Conry RM. Induction of anti-tumor immunity by intrasplenic administration of a carcinoembry-onic antigen DNA vaccine. J Gene Med 2000; 2:135-140.
74. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999; 6:1972-1981.
75. Fairbairn LJ, Rafferty JA, Lashford LS. Engineering drug resistance in human cell. Bone Marrow Transplant 2000; 25(Suppl2):S110-S113.
76. Beausejour CM, Le NL, Letourneau S, Cournoyer D, Momparler RL. Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. Hum Gene Ther 1998; 9:2537-2544.
77. Lu JY, Lowe DA, Kennedy MD, Low PS. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target 1999; 7:43-53.
78. Stribbling SM, Friedlos F, Martin J, Davies L, Spooner RA, Marais R, Springer CJ. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther 2000; 11:285-292.
79. Kawamura K, Tasaki K, Hamada H, Takenaga K, Sakiyama S, Tagawa M. Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5- fluorouracil and induces protective immunity. Cancer Gene Ther 2000; 7:637-643.
80. Pawlik CA, Iyengar RV, Krull EJ, Mason SE, Khanna R, Harris LC, Potter PM, Danks MK, Guichard SM. Use of the ornithine decarboxylase promoter to ahieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11. Mol Ther 2000; 1:457-463.
81. Encell LP, Landis DM, Loeb LA. Improving enzymes for cancer gene therapy. Nat Biotechnol 1999; 17:143-147.
82. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 1997; 4:577-585.
83. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther 1998; 5:1705-1711.
84. Kunitomi M, Takayama E, Suzuki S, Yasuda T, Tsutsui K, Nagaike K, Hiroi S, Tadakuma T. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha- fetoprotein gene. Jpn J Cancer Res 2000; 91:343-350.
85. Yoshizato K, Nishi T, Goto T, Dev SB, Takeshima H, Kino T, Tada K, Kimura T, Shiraishi S, Kochi M, Kuratsu JI, Hofmann GA, Ushio Y. Gene delivery with optimized electroporation parameters shows potential for treatment of gliomas. Int J Oncol 2000; 16:899-905.
86. Murayama Y, Tadakuma T, Kunitomi M, Kumai K, Tsutsui K, Yasuda T, Kitajima M. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha- fetoprotein gene. J Surg Oncol 1999; 70:145-149.
87. Waxman DJ, Chen L, Hecht JE, Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab Rev 1999; 31:503-522.
88. Xiang J, Gomez-Navarro J, Arafat W, Liu B, Barker SD, Alvarez RD, Siegal GP, Curiel DT. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer. J Gene Med 2000; 2:97-106.
89. Mclvor RS. Gene therapy of genetic diseases and cancer. Pediatric Transplantation 1999; 3:116-121.
90. Budker V, Budker T, Zhang G, Subbotin V, Loomis A, Wolff JA. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene Med 2000; 2:76-88.
91. Rhodes GH. Immune pathways used in nucleic acid vaccination. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, 1999, pp 379-408.
92. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91:9519-9523.
93. Fan H, Lin Q, Morrissey GR, Khavari PA. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999; 17:870-872.
94. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6:1258-1266.
95. Lui VW, He Y, Falo L, Huang L. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther 2002; 13(2):177-185.
96. Lui VW, Falo LD Jr, Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer-toxicity and attenuation of transgene expression in vivo. J Gene Med 2001; 3(4):384-393.
97. Liu F, Huang L. Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature. J Gene Med 2001; 3(6):569-576.
98. Zhang G, Vargo D, Budker V, Armstrong N, Knechtle S, Wolff JA. Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum Gene Ther 1997; 8:1763-1772.
99. Budker V, Zhang G, Danko I, Williams P, Wolff J. The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther 1998; 5:272-276.
100. Coll JL, Negoescu A, Louis N, Sachs L, Tenaud C, Girardot V, Demeinex B, Brambilla E, Brambilla C, Favrot M. Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum Gene Ther 1998; 9: 2063-2074.
101. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Electrochemotheraphy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993; 72:3694-3700.
102. Goto T, Nishi T, Tamura T, Dev SB, Takeshima H, Kochi M, Yoshizato K, Kuratsu J, Sakata T, Hofmann GA, Ushio Y. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 2000; 97:354-359.
103. Yang N-S, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particel bombardment. PNAS 1990; 87:9568-9572.
104. Tuting T, Gambotto A, Baar J, Davis ID Storkus WJ, Zavodny PJ, Narula S, Tahara H, Robbins PD, Lotze MT. Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther 1997; 4: 1053-1060.
105. Albertini MR, Emler CA, Schell K, Tans KJ, King DM, Sheehy MJ. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle mediated gene transfer. Cancer Gene Ther 1996; 3:192-201.
106. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Yang NS, MacEwen EG. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 1999; 6:26-36.
107. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 1998; 9:1851-1861.
108. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang NS. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93:6291-6296.
109. Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, Paller AS. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol 1999; 112:775-781.
110. Oshikawa K, Ishii Y, Hamamoto T, Sugiyama Y, Kitamura S, Kagawa Y. Particle-mediated gene transfer of murine interleukin-12 cDNA suppresses the growth of Lewis lung carcinoma. In Vivo 1999; 13:397-402.
111. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB, Yang NS. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 1995; 92:2889-2893.
112. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis [see comments] published erratum appears in Nat Med 1995 Mar; 1(3):272]. Nat Med 1995; 1:39-46.
113. Nabel GJ, Nabel E, Yang ZY, Fox BA, Plautz G, Gao X, Huang L, Shu S, Gordon D, Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. PNAS 1993; 90: 11307-11311.
114. Hui KM, Ang PT, Huang L, Tay SK. Phase I study of immunotheraphy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC-DNA-liposome complexes. Gene Ther 1997; 4:783-790.
115. Hara T, Tan Y, Huang L. In vivo delivery to the liver using reconstituted chylomicron remnants as a novel non-viral vector. PNAS 1997; 94:14547-14552.
116. Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ. Proteoglycans mediated cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 1998; 273:26164-26170.
117. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cationmediated gene transfer. PNAS 1996; 93:12349-12354.
118. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid prota-mine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998; 5: 930-937.
119. Xu Y, Szoka FC. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996; 35:5616-5623.
120. Sebestyen MG, Ludtke JJ, Bassik MC, Zhang G, Budker V, Lukhtanov EA, Hagstrom JE, Wolff JA. DNA vector chemistry: the covalent attachment of signal peptides to plasmid DNA. Nat Biotechnol 1998; 16:80-85.
121. Brunner S, Sauer T, Carotta S, Cotten M, Saltik M, Wagner E. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther 2000; 7:401-407.
122. Brisson M, He Y, Li S, Yang JP, Huang L. A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes. Gene Therapy 1999; 6:263-270.
123. Gao X, Huang L. Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomesc. Nucleic Acids Res 1993; 21:2867-2872.
124. Asayama S, Nogawa M, Takei Y, Akaike T, Maruyama A. Synthesis of novel polyampholyte comb-type copolymers consisting of a poly(L-lysine) backbone and hyaluronic acid side chains for a DNA carrier. Bioconjug Chem 1998; 9:476-481.
125. Li S, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther 2000; 7:31-34.
126. Kichler A, Behr J-P, Erbacher P. Polyethylenimines: a family of potent polymers for nucleic acid delivery. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, 1999; pp 191-206.
127. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18: 33-37.
128. Leong KW. Biopolymer-DNA nanospheres. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, 1999, pp 267-287.
129. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999; 16:1273-1279.
130. Wagner E. Ligand-polycation conjugates for receptor-targeted gene transfer. In: Huang L, Hung MC, Wagner E, eds. Nonviral Vectors for Gene Therapy. San Diego: Academic Press, 1999, pp 207-227.
131. Kircheis R, Schuller S, Brunner S, Ogris M, Heider KH, Zauner W, Wagner E. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med 1999; 1:111-120.
132. Aints A, Dilber MS, Smith CI. Intercellular spread of GFP-VP22. J Gene Med 1999; 1:275-279.
133. Phelan A, Elliott G, O’Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16:440-443.
134. Elliott G, O’Hare P. Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division. J Virol 2000; 74:2131-2141.
135. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI, O’Hare P. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6:12-21.
136. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000; 25:35-41.
137. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 2000; 7:896-902.
138. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet 2000; 16:174-181.
139. Anderson LM, Krotz S, Weitzman SA, Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther 2000; 7:845-852.
140. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18:102-110.
141. Vandier D, Calvez V, Massade L, Gouyette A, Mickley L, Fojo T, Rixe O. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. J Natl Cancer Inst 2000; 92:642-647.
142. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 2000; 7:896-902.
143. Shillitoe EJ, Noonan S. Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol 2000; 36:214-220.
144. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000; 11: 1397-1406.
145. Martin V, Cortes ML, de Felipe P, Farsetti A, Calcaterra NB, Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res 2000; 60:3218-3224.
146. Chen X, Zhang D, Dennert G, Hung G, Lee AS. Eradication of murine mammary adenocarcinoma through HSVtk expression directed by the glucose-starvation inducible grp78 promoter. Breast Cancer Res Treat 2000; 59:81-90.
147. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999; 163:1552-1561.
148. Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J, Scheule RK, Cheng SH. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 1999; 10:223-234.
149. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999; 6:1867-1875.
150. Krieg AM. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med 1999; 1:56-63.
151. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, Tuck S, Raz E. Immuno-stimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000; 18:509-514.
152. Yew NS, Zhao H, Wu I-H, Song A, Tousignant JD, Przybylska M, Cheng SH. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Molecular Therapy 2000; 1:1-8.
153. Tan Y, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo [see comments]. Hum Gene Ther 1999; 10:2153-2161.
154. Li S, Wu SP, Whitmore M, Loeffert EJ, Wang L, Watkins SC, Pitt BR, Huang L. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 1999; 276:L796-804